Earnings Call · Q4 FY2025·2026-03-30

Q4 25EPS -100.00%*·Rev n/aQ3 25EPS -10.00%·Rev n/aQ2 25EPS +33.33%·Rev n/aQ1 25EPS -7.69%·Rev n/a⚠ consensus missing

SANGAMO THERAPEUTICS, INC SGMO

Louise Wilkie — Head of Investor Relations and Corporate Communications

Alexander Macrae — Chief Executive Officer

Nathalie Dubois-Stringfellow — Chief Development Officer

−19.4%1d on move date−22.3% vs SPY3d−3.2%5d−16.1%

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more SGMO calls or request research access.

More SGMO calls Browse calls Request research access